Sure do Pete..
1. MSB has product approval, Pluristem does not.
2. The risk of Phase 2 is much much higher than Phase 3 trials, and I seem to recall this Israeli company has been placed on clinical hold once before.
3. Lonza's Singaporean site has been inspected, and approved, by every major regulatory agency. She is suggesting that a site that is doing a Phase 2 process (which the FDA has never inspected or looked at its' quality systems) is better than Lonza's? I don't quite get it.
I detect a whiff of self-interest but I may of course be wrong.
Any comments regarding the validity of these 2 articles?, page-3
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
95.5¢ |
Change
0.005(0.53%) |
Mkt cap ! $1.090B | |||
| Open | High | Low | Value | Volume |
| 95.0¢ | 96.0¢ | 93.5¢ | $2.477M | 2.610M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 14809 | 95.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 95.5¢ | 10582 | 1 |
View Market Depth
| Last trade - 16.10pm 28/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |